These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30382034)

  • 1. [Evidence of Neoadjuvant Treatment for Pancreatic Cancer].
    Kawai M; Yamaue H
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1410-1414. PubMed ID: 30382034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pancreatic cancer. The relative importance of neoadjuvant therapy].
    Beger HG; Poch B; Schwarz M; Gansauge F
    Chirurg; 2003 Mar; 74(3):202-7. PubMed ID: 12647076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of neoadjuvant therapy in pancreatic cancer: a review.
    Russo S; Ammori J; Eads J; Dorth J
    Future Oncol; 2016 Mar; 12(5):669-85. PubMed ID: 26880384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal Malignancies: Pancreatic Cancer Clinical Trials in Neoadjuvant Chemotherapy.
    Barrios P; Chawla A
    Cancer Treat Res; 2024; 192():119-129. PubMed ID: 39212918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer.
    Furuse J; Shibahara J; Sugiyama M
    J Hepatobiliary Pancreat Sci; 2018 May; 25(5):261-268. PubMed ID: 29651809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
    di Sebastiano P; Grottola T; di Mola FF
    Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
    Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of surgery in pancreatic cancer.
    Buanes TA
    World J Gastroenterol; 2017 Jun; 23(21):3765-3770. PubMed ID: 28638216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Advances in Localized Pancreatic Cancer.
    Tsai S; Evans DB
    JAMA Surg; 2016 Sep; 151(9):862-8. PubMed ID: 27276001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status of neoadjuvant therapy for resectable pancreatic cancer.
    Hoffman JP
    Surg Oncol Clin N Am; 2010 Apr; 19(2):411-8. PubMed ID: 20159522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
    Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant therapy vs. upfront resection for resectable pancreatic cancer].
    Strobel O; Büchler MW
    Chirurg; 2017 Jul; 88(7):619. PubMed ID: 28573533
    [No Abstract]   [Full Text] [Related]  

  • 16. [The value of extended surgery for pancreatic cancer in the context of neoadjuvant therapy].
    Zhang TP; Liu YZ; Cao Z
    Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):481-485. PubMed ID: 32610414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New developments in the treatment of pancreatic cancer].
    Marsman HA; Besselink MG
    Ned Tijdschr Geneeskd; 2016; 160():D538. PubMed ID: 27758723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified Appleby Procedure for Pancreatic Adenocarcinoma: Does Improved Neoadjuvant Therapy Warrant Such an Aggressive Approach?
    Peters NA; Javed AA; Cameron JL; Makary MA; Hirose K; Pawlik TM; He J; Wolfgang CL; Weiss MJ
    Ann Surg Oncol; 2016 Oct; 23(11):3757-3764. PubMed ID: 27328946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer.
    Cassinotto C; Sa-Cunha A; Trillaud H
    Diagn Interv Imaging; 2016 Dec; 97(12):1225-1232. PubMed ID: 27692675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.